Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2011
Date: 2012-02-16
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, free movement of goods, market approval, marketing, medicinal product








C_2012044EN.01000601.xml










16.2.2012   


EN


Official Journal of the European Union


C 44/6





Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2011
2012/C 44/05

Subcommittee I on the free movement of goods


To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January-30 June 2011, at their meeting on 30 September 2011:






Annex I


List of new marketing authorisations




Annex II


List of renewed marketing authorisations




Annex III


List of extended marketing authorisations




Annex IV


List of withdrawn marketing authorisations




Annex V


List of suspended marketing authorisations






ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2011:








EU-Number


Product


Country


Date of authorisation




EU/1/09/578/001


Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals


Iceland


29.4.2011




EU/1/10/635/001-014


Olanzapin Apotex


Norway


14.2.2011




EU/1/10/639/001-030


Telmisartan Actavis


Norway


17.3.2011




EU/1/10/641/001


Ruconest


Iceland


24.1.2011




EU/1/10/642/001-004


Ibandronic Acid Teva


Iceland


17.1.2011




EU/1/10/647/001-002


Myclausen


Iceland


21.1.2011




EU/1/10/647/001-028


Twynsta


Iceland


21.1.2011




EU/1/10/650/001-015


Clopidogrel Teva Generics BV


Iceland


1.2.2011




EU/1/10/651/001-015


Clopidogrel HCS


Iceland


1.2.2011




EU/1/10/654/001-004


Leflunomide ratiopharm


Iceland


14.3.2011




EU/1/10/656/001-006


Possia


Iceland


13.1.2011




EU/1/10/656/001-006


Possia


Norway


25.1.2011




EU/1/10/657/001-002


Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Dia


Iceland


14.3.2011




EU/1/10/657/001-002


Prepandemic Influenza Vaccine


Norway


3.1.2011




EU/1/10/658/001-002


Aflunov


Iceland


14.3.2011




EU/1/10/658/001-002


Aflunov


Norway


3.1.2011




EU/1/10/659/001-010


Iasibon


Iceland


14.2.2011




EU/1/10/659/001-010


Iasibon


Norway


17.2.2011




EU/1/10/659/001-010


Iasibon


Liechtenstein


28.2.2011




EU/1/10/660/001-002


Potactasol


Iceland


16.3.2011




EU/1/10/660/001-002


Potactasol


Liechtenstein


28.2.2011




EU/1/10/661/001-002


Fluenz


Iceland


16.3.2011




EU/1/10/661/001-002


Fluenz


Liechtenstein


28.2.2011




EU/1/10/662/001-002


Docetaxel Teva Pharma


Iceland


17.2.2011




EU/1/10/662/001-002


Docetaxel Teva Pharma


Liechtenstein


28.2.2011




EU/1/10/662/001-002


Docetaxel Teva Pharma


Norway


17.3.2011




EU/1/10/662/001-002


Docetaxel Teva Pharma


Norway


17.3.2011




EU/1/10/663/001-002


Lamivudine/Zidovudine Teva


Norway


31.3.2011




EU/1/10/663/001-002


Lamivudine/Zidovudine Teva


Liechtenstein


30.4.2011




EU/1/10/664/001


Pumarix


Iceland


8.4.2011




EU/1/10/664/001


Pumarix


Norway


13.4.2011




EU/1/10/664/001


Pumarix


Liechtenstein


30.4.2011




EU/1/10/665/001-004


Entacapone Teva


Iceland


21.3.2011




EU/1/10/665/001-004


Entacapone Teva


Norway


4.4.2011




EU/1/10/665/001-004


Entacapone Teva


Liechtenstein


30.4.2011




EU/1/11/666/001-003


Libertek


Iceland


24.3.2011




EU/1/11/666/001-003


Libertek


Norway


15.3.2011




EU/1/11/666/001-003


Libertek


Liechtenstein


30.4.2011




EU/1/11/667/001-003


Esbriet


Liechtenstein


30.4.2011




EU/1/11/667/001-003


Esbriet


Iceland


25.3.2011




EU/1/11/667/001-003


Esbriet


Norway


15.3.2011




EU/1/11/667/001-003


Esbriet


Norway


15.3.2011




EU/1/11/668/001-003


Daliresp


Iceland


12.4.2011




EU/1/11/668/001-003


Daliresp


Norway


15.3.2011




EU/1/11/668/001-003


Daliresp


Liechtenstein


30.4.2011




EU/1/11/669/001-004


Teysuno


Iceland


12.4.2011




EU/1/11/669/001-004


Teysuno


Norway


24.5.2011




EU/1/11/669/001-004


Teysuno


Liechtenstein


30.4.2011




EU/1/11/671/001


Xiapex


Iceland


28.3.2011




EU/1/11/671/001


Xiapex


Norway


31.3.2011




EU/1/11/671/001


Xiapex


Liechtenstein


30.4.2011




EU/1/11/672/001-006


Xeplion


Iceland


8.4.2011




EU/1/11/672/001-006


Xeplion


Norway


5.4.2011




EU/1/11/672/001-006


Xeplion


Liechtenstein


30.4.2011




EU/1/11/673/001-024


Ifirmacombi


Iceland


4.4.2011




EU/1/11/673/001-024


Ifirmacombi


Norway


6.4.2011




EU/1/11/673/001-024


Ifirmacombi


Liechtenstein


30.4.2011




EU/1/11/674/001-010


Repso


Iceland


13.4.2011




EU/1/11/674/001-010


Repso


Norway


26.4.2011




EU/1/11/674/001-010


Repso


Liechtenstein


30.4.2011




EU/1/11/675/001-0010


Leflunomide Teva


Iceland


8.4.2011




EU/1/11/675/001-010


Lefluomide Teva


Norway


11.4.2011




EU/1/11/675/001-010


Leflunomid Teva


Liechtenstein


30.4.2011




EU/1/11/676/001


Jevtana


Iceland


12.4.2011




EU/1/11/676/001


Jevtana


Norway


6.4.2011




EU/1/11/676/001


Jevtana


Liechtenstein


30.4.2011




EU/1/11/677/001-004


Gilenya


Iceland


13.4.2011




EU/1/11/677/001-004


Gilenya


Norway


28.3.2011




EU/1/11/677/001-004


Gilenya


Liechtenstein


30.4.2011




EU/1/11/678/001-002


Halaven


Iceland


14.4.2011




EU/1/11/678/001-002


Halaven


Norway


6.4.2011




EU/1/11/678/001-002


Halaven


Liechtenstein


30.4.2011




EU/1/11/679/001-006


Pravafenix


Iceland


10.5.2011




EU/1/11/679/001-006


Pravafenix


Norway


11.5.2011




EU/1/11/679/001-006


Pravafenix


Liechtenstein


30.4.2011




EU/1/11/680/001-080


Riprazo HCT


Iceland


29.4.2011




EU/1/11/680/001-080


Riprazo HCT


Norway


24.5.2011




EU/1/11/680/001-080


Riprazo HCT


Liechtenstein


30.4.2011




EU/1/11/681/001-013


Trobalt


Iceland


19.4.2011




EU/1/11/681/001-013


Trobalt


Norway


4.4.2011




EU/1/11/681/001-013


Trobalt


Liechtenstein


30.6.2011




EU/1/11/681/001-013


Trobalt


Liechtenstein


30.4.2011




EU/1/11/682/001


Methylthioninium chloride Proveblue


Iceland


6.6.2011




EU/1/11/682/001


Methylhionininium chloride Proveblue


Norway


27.6.2011




EU/1/11/682/001


Methylthioninchlorid Proveblue


Liechtenstein


30.6.2011




EU/1/11/686/001-056


Rasilamlo


Iceland


12.5.2011




EU/1/11/686/001-056


Rasilamlo


Norway


24.5.2011




EU/1/11/686/001-056


Rasilamlo


Liechtenstein


30.4.2011




EU/1/11/687/001-012


Hizentra


Iceland


12.5.2011




EU/1/11/687/001-012


Hizentra


Norway


9.5.2011




EU/1/11/687/001-012


Hizentra


Liechtenstein


30.4.2011




EU/1/11/688/001


Cinryze


Iceland


28.6.2011




EU/1/11/688/001


Cinryze


Norway


27.6.2011




EU/1/11/691/001-005


Eliquis


Norway


31.5.2011




EU/1/11/691/001-005


Eliquis


Liechtenstein


30.6.2011




EU/1/11/692/001


Yellox


Iceland


28.6.2011




EU/1/11/692/001


Yellox


Norway


10.6.2011




EU/1/11/692/001


Yellox


Liechtenstein


30.6.2011




EU/1/11/693/001-016


Rivastigmine Actavis


Iceland


28.6.2011




EU/1/11/693/001-016


Rivastigmine Actavis


Liechtenstein


30.6.2011




EU/1/190/649/001-016


Clopidogrel Teva Pharma BV


Iceland


30.6.2011




EU/1/98/058/001-002


Lamivudine/Zidovudine Teva


Iceland


12.4.2011




EU/1/98/058/001-002


Lamivudine


Norway


31.3.2011




EU/2/11/120/001-003


Zulvac 1 + 8 Ovis


Liechtenstein


30.4.2011




EU/2/11/126/001


MS-H Impfstoff


Liechtenstein


30.6.2011




EU/2/10/107/001-014


Veraflox


Iceland


10.5.2011




EU/2/10/107/001-014


Veraflox


Norway


24.6.2011




EU/2/10/107/001-014


Veraflox


Liechtenstein


30.4.2011




EU/2/10/109/001-009


RHINISENG


Norway


3.1.2011




EU/2/10/110/001-002


Coxevac


Iceland


26.1.2011




EU/2/10/111/001-004


Meloxoral


Iceland


14.3.2011




EU/2/10/111/001-004


Meloxoral


Norway


3.1.2011




EU/2/10/112/001-005


BTVPUR ALSap 1


Iceland


10.2.2011




EU/2/10/112/001-005


BTVPUR ALSap 1


Liechtenstein


28.2.2011




EU/2/10/113/001-005


BTVPUR ALSap 1-8


Iceland


10.2.2011




EU/2/10/113/001-005


BTVPUR ALSap 1-8


Liechtenstein


28.2.2011




EU/2/10/114/001-002


Hiprabovis IBR Marker Live


Iceland


16.3.2011




EU/2/10/114/001-002


Hiprabovis IBR Marker Live


Norway


9.2.2011




EU/2/10/114/001-002


Hiprabovis IBR Marker Live


Liechtenstein


28.2.2011




EU/2/10/115/001-010


Comfortis


Iceland


22.3.2011




EU/2/10/115/001-010


Comfortis


Norway


22.2.2011




EU/2/10/115/001-010


Comfortis


Liechtenstein


30.4.2011




EU/2/10/115/001-010


Comfortis


Norway


22.2.2011




EU/2/10/116/001-004


Melosus


Iceland


24.3.2011




EU/2/10/116/001-004


Melosus


Norway


14.4.2011




EU/2/10/116/001-004


Melosus


Liechtenstein


30.4.2011




EU/2/10/117/001-002


Purevax Rabies


Iceland


21.3.2011




EU/2/10/117/001-002


Purevax Rabies


Norway


4.4.2011




EU/2/10/117/001-002


Purevax Rabies


Liechtenstein


30.4.2011




EU/2/10/118/001-014


Activyl


Iceland


21.3.2011




EU/2/10/118/001-014


Activyl


Norway


1.4.2011




EU/2/10/118/001-014


Activyl


Liechtenstein


30.4.2011




EU/2/10/119/001-012


Cimalgex


Iceland


21.3.2011




EU/2/10/119/001-012


Cimalgex


Norway


1.4.2011




EU/2/108/001-005


BTVPUR ALSap 2-4 0.72 U.SN


Iceland


10.2.2011




EU/2/11/120/001-003


Zulvac 1 + 8 Ovis


Iceland


13.4.2011




EU/2/11/120/001-003


Zulvac 1 + 8 Ovis


Norway


18.4.2011




EU/2/11/121/001-009


CaniLeish


Iceland


13.4.2011




EU/2/11/121/001-009


CaniLeish


Norway


11.4.2011




EU/2/11/121/001-009


CaniLeish


Liechtenstein


30.4.2011




EU/2/11/123/001-002


Procox


Iceland


28.6.2011




EU/2/11/123/001-002


Procox


Norway


20.6.2011




EU/2/11/123/001-002


Procox


Liechtenstein


30.6.2011




EU/2/11/124/001-008


Zuprevo


Iceland


6.6.2011




EU/2/11/124/001-008


Zuprevo


Liechtenstein


30.6.2011




EU/2/11/125/001-008


Certifect


Iceland


6.6.2011




EU/2/11/125/001-008


Certificet


Liechtenstein


30.6.2011




EU/2/11/126/001


MS-H-vaccine


Iceland


28.6.2011







ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2011:








EU-Number


Product


Country


Date of authorisation




EU/1/00/135/001-002


DaTSCAN


Iceland


14.3.2011




EU/1/00/149/001


Panretin


Iceland


18.1.2011




EU/1/00/156/002-004


Trizivir


Iceland


14.2.2011




EU/1/00/166/001-003


NeuroBloc


Iceland


15.2.2011




EU/1/00/166/001-003


NeuroBloc


Norway


15.2.2011




EU/1/00/167/001-008


Prevenar


Iceland


25.3.2011




EU/1/00/167/001-008


Prevenar


Norway


3.3.2011




EU/1/00/167/001-008


Prevenar


Liechtenstein


28.2.2011




EU/1/00/173/001-003


Vaniqa


Iceland


15.4.2011




EU/1/01/171/001, 007-010, 013-014


Rapamune


Iceland


21.2.2011




EU/1/01/171/001, EU/1/01/171/007-010
EU/1/01/171/013-014


Rapamune


Norway


2.2.2011




EU/1/01/172/001-008


Kaletra


Iceland


21.3.2011




EU/1/01/172/001-008


Kaletra


Norway


27.4.2011




EU/1/01/172/001-008


Kaletra


Liechtenstein


30.4.2011




EU/1/01/173/001-003


Vaniqa


Norway


3.5.2011




EU/1/01/173/001-003


Vaniqa


Liechtenstein


30.4.2011




EU/1/01/179/001


Osigraft


Iceland


17.5.2011




EU/1/01/179/001


Osigraft


Norway


15.6.2011




EU/1/01/179/001


Osigraft


Liechtenstein


30.6.2011




EU/1/01/183/001&004-005, 007-008, 011, 013, 015, 018-032


HBVAXPRO


Iceland


18.4.2011




EU/1/01/183/001, EU/1/01/183/004-005
EU/1/01/183/007-008, EU/1/01/183/011
EU/1/01/183/013, EU/1/01/183/015
EU/1/01/183/018-032


HBVAXPRO


Norway


14.4.2011




EU/1/01/187/001


DepoCyte


Iceland


23.6.2011




EU/1/01/187/001


DepoCyte


Liechtenstein


30.6.2011




EU/1/01/191/001-005


Ketek 400 mg


Iceland


9.6.2011




EU/1/01/191/001-005


Ketek


Norway


31.5.2011




EU/1/01/191/001-005


Ketek


Liechtenstein


30.6.2011




EU/1/01/193/001-002


MabCampath


Iceland


23.6.2011




EU/1/01/193/001-002


MabCampath


Norway


15.6.2011




EU/1/05/312/001


Xyrem


Iceland


14.1.2011




EU/1/05/313/001-009


Ablavar


Iceland


28.1.2011




EU/1/05/314/001


Kepivance


Iceland


17.1.2011




EU/1/05/315/001-002


Aptivus


Iceland


27.1.2011




EU/1/05/320/001


Noxafil


Iceland


18.1.2011




EU/1/05/322/001


Yttriga


Iceland


18.3.2011




EU/1/05/322/001


Yttriga


Norway


20.1.2011




EU/1/05/322/001


Yttriga


Liechtenstein


28.2.2011




EU/1/05/323/001-013


ProQuad


Iceland


15.4.2011




EU/1/05/323/001-013


ProQuad


Norway


6.4.2011




EU/1/05/323/001-013


ProQuad


Liechtenstein


30.4.2011




EU/1/05/324/001-002


Naglazyme


Iceland


23.3.2011




EU/1/05/324/001-002


Naglazyme


Norway


7.2.2011




EU/1/05/324/001-002


Naglazyme


Liechtenstein


28.2.2011




EU/1/05/325/002


Macugen


Iceland


15.2.2011




EU/1/05/325/002


Macugen


Norway


1.2.2011




EU/1/05/325/002


Macugen


Liechtenstein


28.2.2011




EU/1/05/328/001-004


Cubicin


Iceland


14.2.2011




EU/1/05/328/001-004


Cubicin


Norway


11.1.2011




EU/1/05/329/001-006


Kiovig


Iceland


24.2.2011




EU/1/05/329/001-006


Kiovig


Norway


2.2.2011




EU/1/05/329/001-006


Kiovig


Liechtenstein


28.2.2011




EU/1/05/330/001-011


Rotarix


Iceland


22.3.2011




EU/1/05/330/001-011


Rotarix


Norway


13.5.2011




EU/1/05/331/001-055


Neupro


Iceland


15.2.2011




EU/1/05/331/001-055


Neupro


Norway


10.1.2011




EU/1/06/332/001-009


Omnitrope


Iceland


28.6.2011




EU/1/06/332/001-009


Omnitrope


Norway


5.4.2011




EU/1/06/332/001-009


Omnitrope


Liechtenstein


30.4.2011




EU/1/06/333/001-003


Myozyme


Iceland


20.4.2011




EU/1/06/333/001-003


Myozyme


Norway


22.3.2011




EU/1/06/333/001-003


Myozyme


Liechtenstein


30.4.2011




EU/1/06/334/001-005


Evoltra


Iceland


18.4.2011




EU/1/06/334/001-005


Evoltra


Norway


25.5.2011




EU/1/06/334/001-005


Evoltra


Liechtenstein


30.4.2011




EU/1/06/335/001


Valtropin


Iceland


12.5.2011




EU/1/06/335/001


Valtropin


Norway


3.6.2011




EU/1/06/335/001


Valtropin


Liechtenstein


30.4.2011




EU/1/06/336/001


Tygacil


Norway


31.5.2011




EU/1/06/336/001


Tygacil


Liechtenstein


30.6.2011




EU/1/06/337/001-013


M-M-RVAXPRO


Iceland


16.5.2011




EU/1/06/337/001-013


M-M-RVAXPRO


Norway


31.5.2011




EU/1/06/337/001-013


M-M-RVAXPRO


Liechtenstein


30.6.2011




EU/1/06/338/001-003


DuoTrav


Iceland


21.1.2011




EU/1/06/339/001-002


Preotact


Iceland


11.5.2011




EU/1/06/339/001-002


Preotact


Liechtenstein


30.4.2011




EU/1/06/341/001-013


Zostavax


Iceland


18.4.2011




EU/1/06/341/001-013


Zostavax


Liechtenstein


30.4.2011




EU/1/06/343/001-007


Baraclude


Iceland


23.6.2011




EU/1/06/343/001-007


Baraclude


Liechtenstein


30.6.2011




EU/1/06/346/001


Tysabri


Iceland


27.6.2011




EU/1/06/348/001-002


RotaTeq


Iceland


23.6.2011




EU/1/06/348/001-002


RotaTeq


Norway


17.6.2011




EU/1/06/348/001-002


RotaTeq


Liechtenstein


28.2.2011




EU/1/06/354/001-011


Competact


Iceland


24.6.2011




EU/1/06/354/001-011


Competact


Norway


23.6.2011




EU/1/06/354/001-011


Competact


Liechtenstein


30.6.2011




EU/1/06/360/001-013


Champix


Liechtenstein


30.6.2011




EU/1/06/367/001-012


Diacomit


Iceland


11.2.2011




EU/1/06/367/001-012


Diacomit


Norway


15.2.2011




EU/1/06/367/001-012


Diacomit


Liechtenstein


28.2.2011




EU/1/07/423/001-003


Vectibix


Iceland


15.2.2011




EU/1/07/423/001-003


Vectibix


Norway


25.1.2011




EU/1/07/440/001-003


Tyverb


Norway


3.6.2011




EU/1/10/625/001


Arzerra


Iceland


22.2.2011




EU/1/10/625/001-002


Arzerra


Norway


17.2.2011




EU/1/10/625/001-002


Arzerra


Liechtenstein


28.2.2011




EU/1/10/628/001-004


Votrient


Iceland


6.6.2011




EU/1/183/001, 004-005, 007-008, 011, 013, 015, 018-032


HBVAXPRO


Liechtenstein


30.4.2011




EU/1/96/009/001-008


Zerit


Iceland


16.5.2011




EU/1/96/009/001-009


Zerit


Norway


6.5.2011




EU/1/96/009/001-009


Zerit


Liechtenstein


30.4.2011




EU/2/00/026/001-004


Porcilis AR-T DF


Norway


3.1.2011




EU/2/00/026/001-006


Porcilis AR-T DF


Iceland


17.1.2011




EU/2/04/045/001-007


Previcox


Norway


18.4.2011




EU/2/04/048/001-002


Purevax RCP FeLV


Norway


13.4.2011




EU/2/04/049/001-002


Purevax RCCh


Norway


13.4.2011




EU/2/04/050/001-002


Purevax RCPCh


Norway


13.4.2011




EU/2/04/051/001-002


Purevax RC


Norway


13.4.2011




EU/2/04/052/001-002


Purevax RCP


Norway


13.4.2011




EU/2/06/058/004


Flexicam


Iceland


8.4.2011




EU/2/06/058/004


Flexicam


Norway


26.4.2011




EU/2/06/058/004


Flexicam


Liechtenstein


30.4.2011




EU/2/06/059/001


Convenia


Iceland


27.6.2011







ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2011:








EU-Number


Product


Country


Date of authorisation




EU/1/01/185/100-111


Aranesp


Iceland


15.4.2011




EU/1/01/194/003-004


INOmax


Iceland


15.4.2011




EU/1/02/227/003


Neulasta


Liechtenstein


30.4.2011




EU/1/06/332/010-012


Omnitrope


Iceland


16.6.2011




EU/1/06/332/010-012


Omnitrope


Liechtenstein


30.6.2011




EU/1/06/354/010-011


Competact


Liechtenstein


28.2.2011




EU/1/06/354/012


Competact


Liechtenstein


30.6.2011




EU/1/06/370/037-039


Exforge


Liechtenstein


28.2.2011




EU/1/06/371/037-039


Dafiro


Liechtenstein


28.2.2011




EU/1/06/373/037-039


Imprida


Liechtenstein


28.2.2011




EU/1/07/387/014-026


Advagraf


Liechtenstein


30.6.2011




EU/1/07/397/002-004


Siklos


Iceland


25.3.2011




EU/1/07/397/002-004


Siklos


Norway


5.4.2011




EU/1/07/397/002-004


Siklos


Liechtenstein


30.4.2011




EU/1/07/401/012-015


Alli


Iceland


16.2.2011




EU/1/07/401/012-015


Alli


Norway


26.1.2011




EU/1/07/404/006-008


Flebogamma DIF


Iceland


17.2.2011




EU/1/07/404/006-008


Flebogamma DIF


Norway


14.1.2011




EU/1/07/404/006-008


Flebogamma DIF


Liechtenstein


28.2.2011




EU/1/07/407/021-040


Sprimeo


Liechtenstein


30.4.2011




EU/1/07/410/027-052


Binocrit


Liechtenstein


30.4.2011




EU/1/07/411/027-052


Epoetin alfa Hexal


Liechtenstein


30.4.2011




EU/1/07/420/002


Cyanokit


Iceland


20.1.2011




EU/1/07/420/002


Cyanokit


Norway


14.2.2011




EU/1/07/422/005-006


Tasigna


Iceland


23.3.2011




EU/1/07/422/005-006


Tasigna


Norway


21.1.2011




EU/1/07/422/005-006


Tasigna


Liechtenstein


28.2.2011




EU/1/07/438/005-006


Myfenax


Liechtenstein


30.6.2011




EU/1/07/439/005-006


Mycophenole mofetil Teva


Liechtenstein


30.6.2011




EU/1/08/461/002


Firazyr


Liechtenstein


30.4.2011




EU/1/08/490/017-024


Pramipexole Teva


Liechtenstein


30.6.2011




EU/1/09/511/005


Conbriza


Liechtenstein


30.4.2011




EU/1/09/535/015-016


Grepid


Liechtenstein


28.2.2011




EU/1/09/545/011-015


Onglyza


Iceland


14.4.2011




EU/1/09/545/011-015


Onglyza


Norway


25.3.2011




EU/1/09/545/011-015


Onglyza


Liechtenstein


30.4.2011




EU/1/09/581/003-008


Resolor


Liechtenstein


28.2.2011




EU/1/10/614/002


Menveo


Liechtenstein


30.4.2011




EU/1/96/022/035-040


Zyprexa


Liechtenstein


28.2.2011




EU/1/97/033/005-006


Avonex


Liechtenstein


30.6.2011




EU/1/99/103/005


ReFacto AF


Iceland


6.6.2011




EU/1/99/103/005-008


ReFacto AF


Norway


1.6.2011




EU/1/99/103/005-008


ReFacto AF


Liechtenstein


30.6.2011




EU/2/07/078/009-010


Rheumocam


Iceland


18.4.2011




EU/2/07/078/009-010


Rheumocam


Norway


9.2.2011




EU/2/07/078/009-010


Rheumocam


Liechtenstein


28.2.2011




EU/2/07/078/011-014


Rheumocam


Iceland


28.6.2011




EU/2/07/078/011-014


Rheumocam


Liechtenstein


30.6.2011




EU/2/08/082/007


Zactran


Liechtenstein


30.6.2011




EU/2/97/004/041-048


Metacam


Liechtenstein


28.2.2011




EU/2/98/010/025


Econor


Iceland


18.2.2011




EU/2/98/010/025


Econor


Liechtenstein


28.2.2011




EU/99/119/017-018


NovoRapid


Liechtenstein


30.4.2011







ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2011:








EU-Number


Product


Country


Date of withdrawal




EU/1/03/259/001-006


Onsenal


Iceland


20.4.2011




EU/1/03/259/001-006


Onsenal


Liechtenstein


30.4.2011




EU/1/05/326/001


Ionsys


Iceland


20.4.2011




EU/1/06/353/001-005


Thelin


Iceland


15.3.2011




EU/1/06/353/001-005


Thelin


Liechtenstein


28.2.2011




EU/1/08/449/001-008


Filgrastim ratiopharm


Liechtenstein


30.4.2011




EU/1/08/449/001-008


Filgrastim ratiopharm


Iceland


12.5.2011




EU/1/09/542/001-007


Clopidogrel 1A Pharma


Liechtenstein


28.2.2011




EU/1/09/542/001-007


Clopidogrel 1A Pharma


Iceland


16.3.2011




EU/1/09/547/001-007


Clopidogrel Sandoz


Liechtenstein


30.4.2011




EU/1/10/629/001


Humenza


Iceland


29.6.2011




EU/1/10/629/001


Humenza


Liechtenstein


30.6.2011







ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January-30 June 2011:








EU-Number


Product


Country


Date of suspension




EU/1/00/137/002-018


Avandia


Iceland


13.1.2011




EU/1/03/258/001-022


Avandamet


Iceland


13.1.2011




EU/1/06/349/001-010


Avaglim


Iceland


17.1.2011




EU/2/06/058/001-003


Flexicam


Iceland


14.1.2011




EU/2/08/088/001-003


Acticam


Norway


7.3.2011




EU/2/09/099/001-006


Suvaxyn PCV


Iceland


22.3.2011